Allarity Therapeutics, Inc. announced on September 22, 2025, the presentation of new and updated clinical data from its ongoing Phase 2 clinical trial in advanced ovarian cancer patients. The data, presented at the AACR 7th Biennial Special Conference on Ovarian Cancer, showed that median Overall Survival (mOS) for platinum-resistant and refractory ovarian cancer patients receiving stenoparib now exceeds 25 months.
This Kaplan-Meier analysis provides the first evidence that stenoparib, administered twice daily, may significantly extend patient survival. Notably, this mOS is nearly 10 months longer than reported for the most recent FDA approvals and advances in therapy for platinum-resistant ovarian cancer patients, which typically show mOS of approximately 16-16.5 months.
The data also indicated that stenoparib may provide clinical benefit regardless of BRCA status, including in BRCA wild-type patients, distinguishing it from first-generation PARP inhibitors. The drug continues to show a favorable safety profile with significantly less myelotoxicity, addressing a critical need following the 2022 market withdrawal of some earlier PARP inhibitors in heavily pre-treated ovarian cancer due to lack of long-term survival benefit.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.